assistTek announces collaboration with technology company Mobile ECG / EKG
DOYLESTOWN, Pennsylvania., August 16, 2021 / PRNewswire / – assistTek, an eSource boutique company known for providing customized solutions to support clinical trial teams for two and a half decades, has collaborated with a California healthcare technology company to integrate ECG / EKG capabilities into its eSource platform for clinical trials.
This latest technological integration extends assisTek’s eCOA offerings by enabling the collection and review of real-time ECG / EKG data on any of its eCOA devices, including tablets and smartphones. It also offers increased security and improved data quality and flow, while reducing the burden on the patient.
Integration is the first of its kind.
âIMedrix’s KardioScreen is an innovative, FDA-approved, cloud-connected mobile ECG / EKG device that simplifies the process of cardiac monitoring in a wide variety of settings,â said Cindy howry, assistTek President. âIn the context of a clinical trial, this allows us to allow a complete step in the process. In short, it’s a perfect addition to our growing list of capabilities.
IMedrix Founder and CEO Srikanth (Sree) Jadcherla said the partnership is “an ideal entry for iMedrix into US Pharma’s decentralized clinical trials, and is a continuation of projects iMedrix has led with companies. pharmaceuticals in Asia, Europe, and Africa. “
assistTek has created a video to show how the integration between KardioScreen and the assisTek eCOA platform can serve patients, healthcare providers and clinical researchers: https://youtu.be/eZV4CW2sIcs.
assistTek is an eSource company that provides solutions for electronic data entry in the field and on-site clinical outcome evaluations including Patient Reported Outcomes (PRO), Clinician Reported Outcomes (ClinRO), results reported by observers (ObsRO) and performance results (PerfOs). The company has provided solutions for more than 500 clinical trials while supporting 90 different languages ââin 80 different countries and has experience in 46 therapeutic areas, including rare and ultra-rare diseases.
iMedrix provides cutting edge medical technology through KardioScreen, a fully mobile, 12/6 lead, FDA approved electrocardiogram (ECG or EKG). iMedrix provides diagnostic solutions directly to EMR systems, producing clinical-grade ECG waveforms with proven device accuracy in more than 200,000 ECGs worldwide. iMedrix is ââcommitted to revolutionizing cardiovascular health care with its artificial intelligence (AI), cloud technology and machine learning (ML) for rapid diagnosis and accurate clinical decisions. www.imedrix.com (1-866-IMEDRIX)
FOR MORE INFORMATION:
Vice-President, Commercial Affairs